Protocol Ledger

NCT04511130 · Phase II · TERMINATED

Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Interventional Phase II clinical trial protocol NCT04511130 sponsored by Marker Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-14 Enrollment: 92 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04511130
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)92 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04511130
Protocol FieldVerified Registry Value
NCT IdentifierNCT04511130
Consolidated Lead SponsorMarker Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment92 participants (ACTUAL)
Registered Start Date2020-10-14
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI